statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

IRVINE, Calif., March 30, 2024 (GLOBE NEWSWIRE) -- Regarding a release issued under the same headline on March 29, 2024 by AEON Biopharma, Inc. (NYSE: AEON; AEON.WS), please note that in the first...

CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants

IRVINE, Calif., March 29, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE: AEON; AEON.WS) ( AEON or the Company ), a clinical-stage biopharmaceutical company focused on developing a...

AEON Biopharma Announces Redemption of Public Warrants

Recent end-of-Phase 2 meeting with FDA resulted in alignment on the design and endpoints for the proposed pivotal Phase 3 trials for the preventive treatment of both episodic and chronic migraine...

AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results

FDA and AEON align on the design and endpoints for the proposed pivotal Phase 3 trials for the preventive treatment of both episodic and chronic migraine An interim analysis from the ongoing...

AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine

Open label extension (OLE) Phase 2 data show peak efficacy for all ABP-450 doses and cycles in treating cervical dystonia (CD) occurred early, within 4 weeks; durability of effect was demonstrated 12...

AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference

AEON Biopharma, Inc. is a biopharmaceutical company. It engages in the business of developing proprietary botulinum toxin complex, ABP-450 injection, for debilitating medical conditions. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Irvine, CA.

Watchers	635
52-Wk Low	$1.38
52-Wk High	$17.17

Volume	119,569.00
52-Wk High	$17.17
52-Wk Low	$1.38

AEON AEON Biopharma Inc. - Ordinary Shares - Class A

About

Feed

News

Sentiment

Fundamentals